Compare McCormick & Company, Incorporated (MKC) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McCormick & Company, Incorporated vs Sana Biotechnology Inc — how do they compare? McCormick & Company, Incorporated trades at $53 (market cap $14.22B), while Sana Biotechnology Inc trades at $3.73 (market cap $1.13B). The key difference: McCormick & Company, Incorporated is far larger — about 12.6× Sana Biotechnology Inc's market cap, and McCormick & Company, Incorporated pays a 3.63% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| MKC | SANA | |
|---|---|---|
Market Cap | $14.22B | $1.13B |
Sector | Consumer Staples | Health |
52-Week High | $72.26 | $5.92 |
52-Week Low | $45.60 | $2.68 |
Enterprise Value | $18.82B | $1.05B |
Dividend Yield | 3.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McCormick & Company (MKC) trades at $53.10, down slightly by 0.06% today, with a bullish technical signal from moving averages but overbought RSI readings. The stock shows strong fundamentals with a P/E of 8.8, net income margin of 21.91%, and consistent earnings beats. Recent news highlights the transformative $65 billion Unilever Foods merger planned for 2027, driving positive sentiment and a consensus price target of $59.67.
MKC presents a compelling investment case with undervalued metrics and strategic growth from the Unilever deal, though risks include integration challenges and soft consumer volumes. Analysts are mixed but lean bullish, with 36.67% buy ratings. The stock offers a solid dividend and upside potential, but investors should monitor merger execution and volume trends.
SANA Biotechnology trades at $3.77, up 4.43% today, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $244.17 million for 2025, with negative cash flow from operations, but analyst consensus is strongly positive with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 average price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress driving future profitability, but high cash burn and negative ROE pose significant risks. Upside potential exists if pipeline milestones are met, supported by institutional optimism, though investors face volatility from earnings misses and funding needs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
